
==== Front
J Int Med Res
J Int Med Res
IMR
spimr
The Journal of International Medical Research
0300-0605
1473-2300
SAGE Publications Sage UK: London, England

39301817
10.1177/03000605241276481
10.1177_03000605241276481
Observational Study
Comparison of Qanadli score with conventional risk stratifiers in non-massive pulmonary emboli
Hajsadeghi Shokoufeh 1
Shamsedini Ali 2
Bahadoran Pooriya 2
https://orcid.org/0000-0003-4674-952X
Amouei Erfan 3
https://orcid.org/0000-0003-2139-5956
Mirshafiee Shayan 4
1 Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
2 Department of Cardiology, 440827 Rasoul Akram Hospital, Iran University of Medical Sciences , Tehran, Iran
3 Department of Internal Medicine, 440827 Iran University of Medical Sciences , Tehran, Iran
4 Department of Cardiology, 48439 School of Medicine, Tehran University of Medical Sciences , Tehran, Iran
Shayan Mirshafiee, Tehran University of Medical Sciences, Enghelab Street, Tehran 1416753955, Islamic Republic of Iran. Email: Shayanmirshafiee@gmail.com
9 2024
20 9 2024
52 9 0300060524127648114 3 2024
3 7 2024
© The Author(s) 2024
2024
SAGE Publications
https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Objective

The management and risk stratification of non-massive pulmonary embolism (PE) remain unclear. However, early assessment of PE severity can aid physicians in establishing better treatment milestones. There has been no direct comparison of mortality rates in patients with non-massive PE, and existing data are sometimes contradictory. Therefore, we examined the relationship between the Qanadli index and conventional risk stratifiers in PE.

Methods

We retrospectively analyzed 200 consecutively selected patients diagnosed with PE. The assessment included computed tomography pulmonary angiography, electrocardiography, echocardiography findings, outcomes, and a comparison with the Simplified Pulmonary Embolism Severity Index (SPESI) score. Descriptive, regression, and receiver operating characteristic analyses were performed.

Results

The mean Qanadli score was 13.5 ± 1.15. Pearson correlation analysis revealed significant associations between the total Qanadli score and several variables: right ventricular enlargement, follow-up ejection fraction, and SPESI score. Although the Qanadli score did not significantly predict mortality, the risk of death increased by 58.8% for each 1-unit increase in the SPESI score.

Conclusions

Although the Qanadli index is valuable in assessing PE and guiding treatment strategies, its standalone predictive value for mortality may be insufficient. Therefore, incorporating scoring systems such as the SPESI and echocardiographic findings is recommended for more accurate mortality prediction.

Pulmonary embolism
Qanadli score
SPESI score
mortality prediction
risk stratification
echocardiography
typesetterts2
==== Body
pmcIntroduction

Pulmonary embolism (PE) ranks as the third most prevalent cardiovascular disease, with an estimated mortality rate of up to 30% without treatment.1–3 According to the European Society of Cardiology (ESC), the incidence of PE is 50 cases per 100,000 people, leading to 100,000 deaths annually in the United States and 300,000 deaths in Europe.4–7

Managing PE is challenging because of its diverse clinical presentations, ranging from asymptomatic findings on computed tomography pulmonary angiography (CTPA) to hemodynamic instability and sudden death.1,8,9 Given the variety of treatment options, including anticoagulants, fibrinolytics, percutaneous catheter-directed therapy, and surgical embolectomy, a risk-adjusted approach to treatment is crucial. 10 As a result, numerous studies have explored risk stratification methods for patients with non-massive PE, though this topic remains controversial.

Currently, CTPA is the primary diagnostic tool for PE.4,11 This has prompted several studies investigating its role in risk stratification for PE. The CT obstruction index, also known as the Qanadli index (QI), is a quantitative method for assessing PE severity; however, its use in risk stratification has been debated. 12 Some studies have demonstrated its independent predictive value for mortality and chronic thromboembolic pulmonary hypertension, while others have not found such associations.13–21

In addition, right ventricular (RV) indices have been shown to predict mortality, and in line with ESC guidelines, RV dysfunction can be used in a risk-adjusted treatment approach for patients with PE.10,21,22 This study focused on exploring the association between the QI score, electrocardiography findings, echocardiography findings, and outcomes (mortality and morbidity), while also comparing the QI score with the Simplified Pulmonary Embolism Severity Index (SPESI) score, a well-established risk stratification method, 23 in patients with non-massive PE.

Methods

Patients and profiles

This retrospective cohort study involved 200 patients aged ≥18 years who were admitted with a diagnosis of pulmonary thromboembolism between January 2014 and March 2019 at Rasoul Akram Hospital, Tehran, Iran. The study assessed CTPA, electrocardiography, and echocardiography findings, as well as mortality, morbidity, and comparisons with the SPESI score. All individual details were de-identified in accordance with ethical considerations, and the reporting of the study adheres to the STROBE guidelines. 24

An unstable hemodynamic state was defined as a systolic blood pressure (SBP) of <100 mmHg and/or diastolic blood pressure of <60 mmHg, a respiratory rate of >30 breaths per minute, a heart rate of >110 beats per minute, or oxygen saturation of <90%. Bed rest was defined as immobilization for more than 3 days or prolonged travel (>4 hours), and obesity was defined as a body mass index of >30 kg/m2.

The SPESI score was determined by factors including age of >80 years, history of cancer, history of chronic cardiopulmonary disease, heart rate of >110 beats per minute, SBP of <100 mmHg, and oxygen saturation of <90%. 25 Echocardiographic findings were measured according to the latest guidelines, and the QI score was calculated using the formula ∑ ([n × d]/40) × 100. Here, n represents the number of segmental branches distal to the proximal thrombus in the pulmonary arterial tree (ranging from 1 to 20), and d represents the degree of obstruction (ranging from 0 to 2) (Figure 1). 12

Figure 1. Qanadli index score measurement. The QI score was calculated using the formula ∑ ([n × d]/40) × 100. Here, n represents the number of segmental branches distal to the proximal thrombus in the pulmonary arterial tree (ranging from 1 to 20), and d represents the degree of obstruction (ranging from 0 to 2). PE, pulmonary embolism.

Echocardiography and CTPA determination

Two-dimensional transthoracic echocardiography was performed within 6 hours of clinical suspicion of PE using a GE Vivid E9™ cardiac ultrasound system (GE HealthCare, Chicago, IL, USA). Experienced echocardiographers, blinded to the QI score, analyzed videotaped examinations. The quantitative assessment of the right ventricle was conducted according to the latest ESC guidelines using the apical four-chamber view.

All patients also underwent standard CTPA within 6 hours. A total of 50 mL of Visipaque™ (iodixanol) was administered. The CT scans were reviewed by two radiologists who were blinded to the echocardiographic findings, and the QI score was calculated as previously described.

Statistical analysis

The t-test or Wilcoxon signed-rank test was used to compare dependent variables across different time points. Receiver operating characteristic (ROC) and Cox hazard analyses were performed, with a significance level set at 0.05. Spearman’s test was employed to assess correlations between quantitative variables, while qualitative variables were analyzed using the Mann–Whitney test or Kruskal–Wallis test, as appropriate. Interobserver variability was determined for both CT and echocardiographic indices.

Quantitative variables between groups were compared using the t-test, and qualitative variables at different time points were compared using the chi-squared test. The results were expressed as absolute and percentage frequencies for qualitative variables and as mean ± standard deviation for quantitative variables. Data analysis was conducted using IBM SPSS version 26 software (IBM Corp., Armonk, NY, USA).

Results

Descriptive findings

A total of 200 individuals participated in this study, including 108 (54%) men and 92 (46%) women. Their mean age was 58.8 ± 18.8 years, and 14% of patients presented with SBP of <100 mmHg (Table 1). Nearly half of the patients experienced dyspnea at rest (44.5%), approximately one-third had an SPESI score of >1, and more than one-quarter exhibited elevated troponin levels (Table 2).

Table 1. Basic and demographic characteristics.

	Frequency	Percent	
Age (years)	
 >80	33	16.5	
 60–80	63	31.5	
 40–60	59	29.5	
 >40	45	22.5	
 Mean ± SD	58.8 ± 18.81	
Sex	
 Male	108	54	
 Female	92	46	
Job	
 High activity	38	22.1	
 Low activity	162	77.9	
Current smoker	46	23.4	
Unstable hemodynamics	33	16.5	
Systolic blood pressure (mmHg)	
 >100	172	86	
 <100	28	14	
 Mean ± SD	123.42 ± 20.84	
Diastolic blood pressure (mmHg)	
 >60	170	85	
 <60	30	15	
 Mean ± SD	79.13 ± 39.51	
Heart rate (beats/min)	
 >110	153	76.5	
 <110	47	23.5	
 Mean ± SD	95.80 ± 20.66	
Respiratory rate (breaths/min)	
 >30	11	5	
 <30	189	95	
 Mean ± SD	19.31 ± 6.04	
Oxygen saturation (on room air)	
 >90%	64	34	
 <90%	126	66	
 Mean ± SD	98.15 ± 10.38	
SD, standard deviation.

Table 2. Basic clinical and paraclinical findings.

	Frequency	Percent	
NYHA functional class	
 I	7	3.5	
 II	26	13	
 III	78	39	
 IV	89	44.5	
SPESI score	
 <1	136	68	
 >1	64	32	
First episode of PE	64	35.8	
History of coronary artery disease	72	36	
History of pulmonary disease	54	27	
Presentation symptom	
 Dyspnea	180	90	
 Cough	10	5	
 Other	10	5	
Admission duration	
 <1 week	189	95	
 >1 week	11	5	
Thrombolytic administration	10	5	
Mortality (during admission)	16	8	
Mortality (during first month after discharge)	4	2	
Mortality (during 6 months after discharge)	13	6.5	
Troponin	
 >100	39	27.5	
 <100	103	72.5	
CRP (mg/dL)	
 >8	87	76.3	
 <8	27	23.7	
WBC (cells/mm3)	
 <11,000	168	16	
 >11,000	32	84	
Pro-BNP (pg/mL)	
 >300	26	61.9	
 <300	16	38.1	
ESR (mm/h)	
 >20	86	77.5	
 <20	25	22.5	
RV enlargement	78	39	
D-dimer (ng/mL)	
 >500	58	93.5	
 <500	4	6.5	
Ferritin (ng/mL)	
 >60	25	73.5	
 <60	9	26.5	
LDH (U/L)	
 >215	128	64	
 <215	72	36	
Hemoglobin (g/dL)	
 >12	97	57.7	
 <12	71	42.3	
D-shaped LV	57	28.5	
Patent foramen ovale	1	0.5	
McConnell’s sign	45	22.5	
Pulmonary arterial hypertension	132	66.3	
TR severity	
 Mild	123	61.9	
 Moderate	53	26.4	
 Severe	24	11.7	
RV dysfunction	
 Mild	58	29	
 Moderate	44	22	
 Severe	28	14	
Pulmonary systolic arterial pressure	
 <35 mmHg	71	35.7	
 >35 mmHg	128	64.3	
IVC diameter	
 <2.1 cm	173	86.9	
 >2.1 cm	26	13.1	
Ejection fraction	
 >50%	127	5	
 40%–50%	62	31.2	
 <40%	10	63.8	
Sinus tachycardia	153	76.9	
S1Q3T3 pattern	68	34.2	
RV strain	30	15.1	
Right bundle branch block	14	7	
Right axis deviation	10	5	
Atrial fibrillation	12	6	
NYHA, New York Heart Association; SPESI, Simplified Pulmonary Embolism Severity Index; PE, pulmonary embolism; CRP, C-reactive protein; WBC, white blood cell count; pro-BNP, pro-brain natriuretic peptide; ESR, erythrocyte sedimentation rate; RV, right ventricular; LV, left ventricle; LDH, lactate dehydrogenase; TR, tricuspid regurgitation; IVC, inferior vena cava.

The mean QI score was 13.5 ± 1.15. Significant associations were found between the total QI score and various clinical variables, including RV enlargement (p = 0.002), McConnell’s sign (p = 0.007), pulmonary arterial hypertension (r = 0.19, p = 0.007), tricuspid regurgitation severity (p = 0.009), pulmonary artery pressure (r = 0.14, p = 0.049), 4-month follow-up ejection fraction (r = −0.41, p = 0.006), SPESI score (p = 0.002), pro-BNP level (p < 0.001), and systolic blood pressure (r = −0.17, p = 0.019).

The analysis focused on assessing the QI score’s predictive ability for mortality. Further details are provided in Table 3. The area under the ROC curve was 70.1%, indicating fair predictive performance. A QI score cut-off of 27.41 yielded a sensitivity of 68.7% and specificity of 69.5% (Figure 2).

Table 3. Correlation/comparison between Qanadli score and clinical variables.

	p		p		p	
Thrombolytic	0.058	S1Q3T3	0.234	RV dysfunction	0.788	
Cancer	0.788	RV strain	0.221	PAP	0.049	
SPESI score	0.082	RBBB	0.306	IVC diameter	0.272	
Presentation	0.776	RAD	0.4	Ejection fraction	0.444	
Troponin	0.686	AF	0.237	IVC reflux	0.171	
CRP	0.104	STD	0.416	Pulmonary aortic enhancement	0.267	
WBC	>0.05	T inversion	0.13	RV.LV	0.331	
Pro-BNP	0.064	Systolic blood pressure	0.019	PA.AO	0.436	
ESR	0.143	Heart rate	0.098	SPESI score	0.069	
Platelet	>0.05	Respiratory rate	0.064	Presentation	0.262	
D dimer	0.594	Unstable hemodynamics	0.112	RV enlargement (4-month F/U)	0.554	
Ferritin	0.291	Oxygen saturation	0.495	D-shaped LV (4-month F/U)	0.744	
LDH	>0.05	RV enlargement	0.002	PFO (4-month F/U)	0.153	
Hb	0.245	D-shaped septum	0.162	McConnell’s sign (4-month F/U)	0.153	
Death at hospital	0.2	Patent foramen ovale	0.79	PAH (4-month F/U)	0.538	
Death after 1 month	0.129	McConnell’s sign	0.048	TR severity (4-month F/U)	0.869	
Death after 6 months	0.564	PAH	0.007	RV dysfunction (4-month F/U)	0.258	
Sinus tachycardia	0.52	TR severity	0.009	SPAP (4-month F/U)	0.09	
				Ejection fraction (4-month F/U)	0.006	
The table presents correlations and comparisons between the Qanadli score and several quantitative and qualitative variables using appropriate statistical tests. Significant associations were found with RV enlargement (p = 0.002), McConnell’s sign (p = 0.007), PAH (r = 0.19, p = 0.007), tricuspid regurgitation severity (p = 0.009), pulmonary artery pressure (r = 0.14, p = 0.049), 4-month follow-up ejection fraction (r = −0.41, p = 0.006), SPESI score (p = 0.002), pro-BNP level (p < 0.001), and systolic blood pressure (r = −0.17, p = 0.019).

RV, right ventricular; PAP, pulmonary artery pressure; IVC, inferior vena cava; SPESI, Simplified Pulmonary Embolism Severity Index; RBBB, right bundle branch block; RAD, right axis deviation; AF, atrial fibrillation; STD, ST depression; RV.LV, right ventricle to left ventricle ratio; PA.AO, pulmonary artery to aorta ratio; F/U, follow-up; PFO, patent foramen ovale; PAH, pulmonary arterial hypertension; TR, tricuspid regurgitation; SPAP, systolic pulmonary artery pressure; S1Q3T3, S wave in lead I, Q wave in lead III, T wave inversion in lead III pattern; RV strain, right ventricular strain; T inversion, T wave inversion; CRP, C-reactive protein; WBC, white blood cell count; Pro-BNP, pro-brain natriuretic peptide; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; Hb, hemoglobin; LV, left ventricle.

Figure 2. The area under the ROC curve for the Qanadli score was 70.1%, with a Qanadli score cut-off of 27.41, suggesting fair performance by a sensitivity of 68.7% and a specificity of 69.5%. ROC, receiver operating characteristic.

Although the QI score did not significantly predict mortality, the risk of death increased by 58.8% for each 1-point increase in the SPESI score. Cox proportional hazard models revealed that only the SPESI score was significantly associated with increased mortality in both the adjusted and crude models (Table 4).

Table 4. Cox proportional hazard models for Qanadli and SPESI scores.

Variable	Hazard ratio for death	p-value	95% CI	
Qanadli score	
 Crude	0.987	0.744	0.914	1.066	
 Adjusted	0.974	0.501	0.901	1.052	
SPESI score	
 Crude	1.644	0.013	1.109	2.438	
 Adjusted	1.588	0.029	1.048	2.406	
Only the SPESI score exhibited a significant increase in mortality in both the adjusted and crude models.

SPESI, Simplified Pulmonary Embolism Severity Index; CI, confidence interval.

Discussion

Given the ongoing controversy surrounding the management of patients with PE, particularly those with sub-massive PE, this study primarily examined the relationship between the QI score and patient outcomes, aiming to explore the potential of the QI score as a new indicator for thrombolytic therapy.

This retrospective study assessed the characteristics of 200 patients with non-massive PE, including their demographic, echocardiographic, electrocardiographic, and CTPA data. The findings showed a higher proportion of male than female patients and a four-fold higher likelihood of mortality in patients aged >80 than <80 years. Thrombolytic therapy was administered to 5% of patients. The in-hospital, 1-month, and 6-month mortality rates were 14.5%, 2.0%, and 6.5%, respectively. Furthermore, 6.5% of patients had a QI score of >20 (QI > 50), 1.5% had a left-sided QI score of >25, and 5% had a right-sided QI score of >25.

A significant relationship was observed between the total QI score and variables such as RV enlargement, McConnell’s sign, pulmonary arterial hypertension, tricuspid regurgitation severity, pulmonary artery pressure, 4-month follow-up ejection fraction, and SBP. However, the common occurrence of a higher right-sided QI score and worse outcomes did not yield a significant relationship with mortality. In addition, the total QI score did not demonstrate a significant association with mortality or unstable hemodynamics, indicating its limited predictive ability for mortality risk. However, significant associations were found between mortality and factors such as tricuspid regurgitation severity, RV dysfunction, unstable hemodynamics, erythrocyte sedimentation rate, C-reactive protein level, pro-BNP level, SPESI score, inferior vena cava diameter, and D-dimer level, suggesting that patients with non-massive PE may benefit from more advanced treatments, including thrombolytic therapy.

Qanadli et al. 12 compared the CT obstruction index and pulmonary arterial obstruction on angiography (assessed by the Miller index) and correlated these findings with echocardiography using linear regression. They demonstrated that a specific CT index could quantify the degree of arterial obstruction in PE, showing reproducibility and a high correlation with the index obtained through pulmonary angiography. 12 Our findings are consistent with their research, recognizing the QI score as a reliable and appropriate index for CTPA. Similarly, Aribas et al. 26 used the QI score and found it to be a reliable and appropriate index for CTPA.

Similar to these studies, Rodrigues et al. 27 and Attinà et al. 28 identified a relationship between the QI score and mortality. However, unlike our research, they reported a significant p-value, possibly due to differences in population size, data variability, and study design. By contrast, Furlan et al. 29 found that the clot burden shown by CTPA was not associated with short-term mortality, which aligns with our findings.

A study conducted in the United States in 2016 titled “CTPA-based scoring system to predict the prognosis of acute pulmonary embolism” by Kumamaru et al. 30 analyzed 1698 consecutive positive CTPAs at a single institution from 2003 to 2010. Two radiologists independently assessed each study for clinically relevant findings and conducted adjudication. 30 These variables, along with patient information, were used to develop a LASSO logistic regression model for predicting 30-day mortality. The final model generated a point score for each significant variable, and the PESI score was calculated for 568 patients who visited the hospital after 2007. Notably, the CTPA-based model demonstrated superior predictive ability for 30-day mortality compared with the PESI. Incorporating the CTPA-based scoring system into image interpretation workflows was suggested to help physicians select the most appropriate management approach for individual patients.

In our analysis, the performance of the QI score as a predictor of mortality was evaluated. The area under the ROC curve was 70.11%, indicating moderately fair predictive ability. Despite the QI score not showing a significant hazard for death, our adjusted model indicates that each 1-unit increase in the SPESI score increased the risk of death by 58.5%. Our study revealed a significant correlation between mortality and SPESI score criteria, which include laboratory data and echocardiographic findings, contradicting the results of the aforementioned studies.27,28,30

A German study involving 246 patients examined the Mastora score, an alternative method for assessing pulmonary vessel obstruction. The study concluded that thrombotic occlusion of pulmonary vessels is not associated with the clinical severity of PE, consistent with our findings regarding the lack of a significant correlation between the QI score and mortality. 31

Akhoundi et al. 32 also highlighted the inefficacy of the QI score in predicting mortality. They suggested enhancing the QI score by integrating the RV/LV ratio to create a combined QI score for better mortality prediction because the QI score alone lacks this predictive ability. 32 Notably, their study did not include a comparison between the QI score and the SPESI score.

The main limitations of this study are its single-center design and the restricted sample size of 200 patients. These limitations could be addressed by conducting multicenter studies with larger sample sizes.

Conclusion

Despite the advantages of the QI score in assessing PE and guiding treatment strategies, its standalone predictive value for mortality may be insufficient. Therefore, using scoring systems such as the SPESI and incorporating echocardiographic findings could be more beneficial for mortality prediction.

Acknowledgements

The authors express their appreciation to the healthcare workers, nurses, and doctors who provided care to the patients evaluated in this study.

Data availability statement

The data supporting the findings of this study can be requested from the corresponding author. They are not publicly accessible because of privacy or ethical restrictions.

Ethical considerations

This study was approved by the Ethics Committee of Iran University of Medical Sciences (approval no. IR.IUMS.FMD.REC.1399.677). Prior to the study’s commencement, all participants were informed about the study and provided verbal informed consent for publication.

Author contributions: SH: design and conceptualization, critical revision. AS: clinical data collection, critical revision, data analysis and interpretation. PB and EA: clinical data collection, laboratory data collection, drafting. SM was the corresponding author who revised, edited, and finalized the final manuscript. All the authors approved the final version of the manuscript.

The authors declare that they have no conflict of interest.

Funding: The authors did not receive support from any organization for the submitted work.

ORCID iDs: Erfan Amouei https://orcid.org/0000-0003-4674-952X

Shayan Mirshafiee https://orcid.org/0000-0003-2139-5956
==== Refs
References

1 Bĕlohlávek J Dytrych V Linhart A. Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol 2013; 18 : 129–138.23940438
2 Laporte S Mismetti P Décousus H , RIETE Investigators et al . Clinical predictors for fatal pulmonary embolism in 15 520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117 : 1711–1716. DOI: 10.1161/CIRCULATIONAHA.107.726232.18347212
3 Stein PD Matta F. Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Crit Care Clin 2011; 27 : 907–932, vii. DOI: 10.1016/j.ccc.2011.09.006.22082520
4 Torbicki A Perrier A Konstantinides S , et al . Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29 : 2276–2315. DOI: 10.1093/eurheartj/ehn310.18757870
5 Horlander KT Mannino DM Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003; 163 : 1711–1717. DOI: 10.1001/archinte.163.14.1711.12885687
6 Konstantinides SV Torbicki A Agnelli G , et al . 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014; 35 : 3033–3080.25173341
7 Beckman MG Hooper WC Critchley SE , et al . Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38 : S495–S501.20331949
8 Carson JL Kelley MA Duff A , et al . The clinical course of pulmonary embolism. N Engl J Med 1992; 326 : 1240–1245.1560799
9 Pollack CV Schreiber D Goldhaber SZ , et al . Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011; 57 : 700–706.21292129
10 Konstantinides SV Meyer G Becattini C , et al . 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 2020; 41 : 543–603.31504429
11 Patel P Patel P Bhatt M , et al . Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism. Blood Adv 2020; 4 : 4296–4311.32915980
12 Qanadli SD El Hajjam M Vieillard-Baron A , et al . New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. Ajr Am J Roentgenol 2001; 176 : 1415–1420.11373204
13 Méan M Tritschler T Limacher A , et al . Association between computed tomography obstruction index and mortality in elderly patients with acute pulmonary embolism: a prospective validation study. PLoS One 2017; 12 : e0179224.28594950
14 Bazeed MF Saad A Sultan A , et al . Prediction of pulmonary embolism outcome and severity by computed tomography. Acta Radiol 2010; 51 : 271–276.20105093
15 Kumar BP Rajasekhar D Vanajakshamma V. Study of clinical, radiological and echocardiographic features and correlation of Qanadli CT index with RV dysfunction and outcomes in pulmonary embolism. Indian Heart J 2014; 66 : 629–634.25634397
16 Van der Meer RW Pattynama PMT Van Strijen MJL , et al . Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology 2005; 235 : 798–803.15845793
17 Faghihi Langroudi T Shabestari AA Hekmati S , et al . Association between pulmonary arterial obstruction index and right lateral ventricular wall thickness with in-hospital mortality in patients with acute pulmonary embolism. Emerg Radiol 2021; 28 : 327–331.33184737
18 Ghaye B Ghuysen A Willems V , et al . Severe pulmonary embolism: pulmonary artery clot load scores and cardiovascular parameters as predictors of mortality. Radiology 2006; 239 : 884–891.16603659
19 Ghuysen A Ghaye B Willems V , et al . Computed tomographic pulmonary angiography and prognostic significance in patients with acute pulmonary embolism. Thorax 2005; 60 : 956–961.16131526
20 Vedovati MC Germini F Agnelli G , et al . Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism: systematic review and meta‐analysis. J Thromb Haemost 2013; 11 : 2092–2102.24134450
21 Meinel FG Nance JW Schoepf UJ , et al . Predictive value of computed tomography in acute pulmonary embolism: systematic review and meta-analysis. Am J Med 2015; 128 : 747–759.e2.25680885
22 Ten Wolde M Söhne M Quak E , et al . Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004; 164 : 1685–1689.15302640
23 Wells P Peacock WF Fermann GJ , et al . The value of sPESI for risk stratification in patients with pulmonary embolism. J Thromb Thrombolysis 2019; 48 : 149–157.30729377
24 Von Elm E Altman DG Egger M , et al . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370 : 1453–1457.18064739
25 Jiménez D Aujesky D Moores L , RIETE Investigators et al . Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170 : 1383–1389.20696966
26 Aribas A Keskin S Akilli H , et al . The use of axial diameters and CT obstruction scores for determining echocardiographic right ventricular dysfunction in patients with acute pulmonary embolism. Jpn J Radiol 2014; 32 : 451–460.24819998
27 Rodrigues B Correia H Figueiredo Â , et al . Clot burden score in the evaluation of right ventricular dysfunction in acute pulmonary embolism: quantifying the cause and clarifying the consequences. Rev Port Cardiol 2012; 31 : 687–695.23062526
28 Attinà D Valentino M Galiè N , et al . Application of a new pulmonary artery obstruction score in the prognostic evaluation of acute pulmonary embolism: comparison with clinical and haemodynamic parameters. Radiol Med 2011; 116 : 230–245.21311989
29 Furlan A Aghayev A Chang CC , et al . Short-term mortality in acute pulmonary embolism: clot burden and signs of right heart dysfunction at CT pulmonary angiography. Radiology 2012; 265 : 283–293.22993221
30 Kumamaru KK Saboo SS Aghayev A , et al . CT pulmonary angiography-based scoring system to predict the prognosis of acute pulmonary embolism. J Cardiovasc Comput Tomogr 2016; 10 : 473–479.27591768
31 Lerche M Bailis N Akritidou M , et al . Pulmonary vessel obstruction does not correlate with severity of pulmonary embolism. J Clin Med 2019; 8 : 584.31035342
32 Akhoundi N Sedghian S Siami A , et al . Does adding the pulmonary infarction and right ventricle to left ventricle diameter ratio to the Qanadli index (a combined Qanadli index) more accurately, predict short-term mortality in patients with pulmonary embolism? Indian J Radiol Imaging 2023; 33 : 478–483.37811186
